Advertisement

Host Response

  • Deshratn Asthana
  • Margaret Fischl
  • Hedy Teppler
  • G. Diego Miralles
  • Kent J. Weinhold

Keywords

Human Immunodeficiency Virus Natural Killer Cell Human Immunodeficiency Virus Type Plasma Viremia Clinical Latency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weiss RA: How does HIV cause AIDS? Science 1993, 260:1273–1279.PubMedCrossRefGoogle Scholar
  2. 2.
    Mellors JW, Rinaldo CR, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167–1170.PubMedCrossRefGoogle Scholar
  3. 3.
    Pantaleo G, Graziosi C, Fauci AS: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993, 328–335.Google Scholar
  4. 4.
    Haase AT: Population biology of HIV-1 infection: viral and CD4+ T-cell. Ann Rev Immunol 1999, 17: 625–656.CrossRefGoogle Scholar
  5. 5.
    Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123–126.PubMedCrossRefGoogle Scholar
  6. 6.
    Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117–122.PubMedCrossRefGoogle Scholar
  7. 7.
    Cohen OJ, Pantaleo G, Holodniy M, et al.: Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA 1995,92:6017–6021.PubMedCrossRefGoogle Scholar
  8. 8.
    Fauci AS: Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993, 262:1011–1018.PubMedCrossRefGoogle Scholar
  9. 9.
    Cao Y, Qin L, Zhang L, et al.: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332:201–208.PubMedCrossRefGoogle Scholar
  10. 10.
    Pantaleo G, Menzo S, Vaccarezza M, et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209–216.PubMedCrossRefGoogle Scholar
  11. 11.
    Kirchhoff F, Greenough TC, Brettler DB, et al: Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995, 332:228–232.PubMedCrossRefGoogle Scholar
  12. 12.
    Baltimore A: Lessons from people with nonprogressive HIV infection [editorial]. N Engl J Med 1995, 332:259–260.PubMedCrossRefGoogle Scholar
  13. 13.
    Bryson YJ, Pang S, Wei LS, et al.: Clearance of HIV infection in a perinatal-ly infected infant. N Engl J Med 1995, 332:833–838.PubMedCrossRefGoogle Scholar
  14. 14.
    Mcintosh K, Burchett SK: Clearance of HIV—Lessons from newborns. N Engl J Med 1995, 332:883–884.PubMedCrossRefGoogle Scholar
  15. 15.
    Young JAT: Basic Science and Pathogenesis of HIV. In The AIDS Knowledge Base,e6n. 3. Edited by Cohen PT, Sande MA, et al.Philadelphia: Lippincott Williams & Wilkins, 1999.Google Scholar
  16. 16.
    Berger EA, Murphy PA, Farber JM: Chemokine receptors as HIV-1 core-ceptors: roles is viral entry, tropism and disease. Ann Rev Immunol 1999, 17:657–700.CrossRefGoogle Scholar
  17. 17.
    Parren PWHI, Mondor I, Naniche D, et al: Neutralization of human immunodeficiency virus type-1 by antibody to gp 120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 1998, 72:3512–3519.PubMedGoogle Scholar
  18. 18.
    Bolognesi D: Do antibodies enhance the infection of cells by HIV? Nature 1989,340:431–432.PubMedCrossRefGoogle Scholar
  19. 19.
    Ullum H, Lepri AC, Aladdin H, et al: Natural immunity and HIV disease progression. AIDS 1999, 13:557–563.PubMedCrossRefGoogle Scholar
  20. 20.
    Karzon DT: Preventive vaccines. In Broder S, Merigan TC, Bolognesi D (eds.): Textbook of AIDS Medicine. Baltimore: Williams and Wilkins; 1994:671.Google Scholar
  21. 21.
    Clerici M, Shearer GM: A Th 1 to Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993, 14:107–111.PubMedCrossRefGoogle Scholar
  22. 22.
    Levy J: HIV pathogenesis and long-term survival. AIDS 1993, 7:1402.CrossRefGoogle Scholar
  23. 23.
    Maggi E, Mazzetti M, Ravina A, et al.: Ability of HIV to promote a TH1 to THO shift and to replicate preferentially in TH2 and THO cells. Science 1994,265:244–248.PubMedCrossRefGoogle Scholar
  24. 24.
    Graziosi C, Pantaleo G, Gantt KR, et al.: Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994,265:248–252.PubMedCrossRefGoogle Scholar
  25. 25.
    Bentwich Z, Kalinkovich A, Weisman Z: Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995, 16(4): 187–191.PubMedCrossRefGoogle Scholar
  26. 26.
    Cohen J: T cell shift: Key to AIDS therapy? Science 1993, 262:175.PubMedCrossRefGoogle Scholar
  27. 27.
    O’Brien WA, Grovit-Ferbas K, Namazi A, et al: Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995, 86(3): 1082–1089.PubMedGoogle Scholar
  28. 28.
    Stanley SK, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222–1230.PubMedCrossRefGoogle Scholar
  29. 29.
    Tasker SA, Treanor JJ, Paxton WB, et al.:Efficacy of influenza vaccination in HIV-infected persons. Ann Intern Med 1999, 131:430–433.PubMedCrossRefGoogle Scholar
  30. 30.
    Staprans SI, Hamilton BL, Follansbee SE, et al.: Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995, 182:1727–1737.PubMedCrossRefGoogle Scholar
  31. 31.
    Fauci AS: Immunology of AIDS and HIV infection. In Mandell GL, Douglas RG Jr, Bennett JE (eds.): Principles and Practice of Infectious Diseases, 3rd ed. New York: Churchill Livingstone; 1990:1049.Google Scholar
  32. 32.
    Jewett A, Cavalcanti M, Giorgi J, et al: Concomitant killing in vitro of both gpl20-coated CD+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system. J Immunol 1997, 158:5492–5500.PubMedGoogle Scholar
  33. 33.
    Staal FJP, Anderson MT, Staal GEJ, et al: Redox regulation of signal transduction: Tyrosine phosphorylation and calcium influx. Proc Natl Acad Sci USA 1994, 91 (9):3619–3622.PubMedCrossRefGoogle Scholar
  34. 34.
    Angier N: Theory tested on why body’s defenses go haywire in AIDS. New York Times 1993; May 3:C3.Google Scholar
  35. 35.
    Katsikis PD, Garcia-Ojeda M, Terres-Roca JF, et al: Interleukin-IB converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV-1 infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV-1 infection. J Exp Med 1997, 186:1365–1372.PubMedCrossRefGoogle Scholar
  36. 36.
    Gougeon MI: Apoptosis in AIDS. Science 1993, 260:1269–1270.PubMedCrossRefGoogle Scholar
  37. 37.
    Ameisen JC: Programmed cell death and AIDS: From hypothesis to experiment. Immunol Today 1992, 13:388.PubMedCrossRefGoogle Scholar
  38. 38.
    Cohen JJ: Apoptosis: The physiologic pathway of cell death. Hosp Pract 1993, (Dec):35.Google Scholar
  39. 40.
    Blatt SP, Hendrix CW, Butzin CA, et al: Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV infected patients. Ann Intern Med 1993, 119:177–184.PubMedCrossRefGoogle Scholar
  40. 40.
    Matsuyama T, Kobayashi N, Yamamoto N: Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease? AIDS 1991, 5:1405–1417.PubMedCrossRefGoogle Scholar
  41. 41.
    Winkler C, Modi W, Smith MW, et al: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998, 279:389–393.PubMedCrossRefGoogle Scholar
  42. 42.
    Poli G, Fauci AS: The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses 1992, 8:191–197.PubMedCrossRefGoogle Scholar
  43. 43.
    Fauci AS: The immune response to HIV infection. In Paul W (ed.): Fundamentals of Immunology, 3rd ed. New York: Raven Press; 1993:1386.Google Scholar
  44. 44.
    Goodkin K, Asthana D: The influence of cytokines and chemokines on the pathophysiology of HIV-1 associated cognitive-motor disorders. Clin Immunol Newsletter 1997, 17:61–65.CrossRefGoogle Scholar
  45. 45.
    Stanley SK, McCune JM, Kaneshima H, et al: Human immunodeficiency virus infection of the human thymus and disruption of the thymic microen-vironment in the SCID-hu mouse. J Exp Med 1993, 178:1151–1163.PubMedCrossRefGoogle Scholar
  46. 46.
    Vigano A, Vella S, Principi N, et al: Thymus volume correlate with the progression of vertical HIV infection. AIDS 1999, 13:F29-F34.CrossRefGoogle Scholar
  47. 47.
    Wong JK, Hezareh M, Gunthard HF, et al: Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291–1295.PubMedCrossRefGoogle Scholar
  48. 48.
    Embretson J, Zupancic M, Ribas JL, et al: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period by AIDS. Nature 1993, 362:359–362.PubMedCrossRefGoogle Scholar
  49. 49.
    Andrieu J-M, Lu W, Levy R: Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 1995, 171:523–530.PubMedCrossRefGoogle Scholar
  50. 50.
    Connick E, Lederman MM, Kotzin BL, et al.: Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000, 181:358–363.PubMedCrossRefGoogle Scholar
  51. 51.
    Corey L: Reducing T cell activation as a therapy for human immunodeficiency virus infection [editorial]. J Infect Dis 1995, 171:521–522.PubMedCrossRefGoogle Scholar

Selected Bibliography

  1. Fauci A: Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993, 262:1011–1018.PubMedCrossRefGoogle Scholar
  2. Matsuyama T, Kobayashi N, Yamamoto N: Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease? AIDS 1991, 5:1405–1417.PubMedCrossRefGoogle Scholar
  3. Pantaleo G, Graziosi C, Fauci AS: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993, 328:327–335.PubMedCrossRefGoogle Scholar
  4. Rosenberg Z, Fauci A: Immunology of HIV Infection. In Paul WE (ed.): Fundamental Immunology, 3rd ed. New York: Raven Press, 1993.Google Scholar
  5. Weiss R: How does HIV cause AIDS? Science 1993, 260:1273–1279.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Deshratn Asthana
  • Margaret Fischl
  • Hedy Teppler
  • G. Diego Miralles
  • Kent J. Weinhold

There are no affiliations available

Personalised recommendations